Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy

被引:249
|
作者
Frangogiannis, Nikolaos G.
Dewald, Oliver
Xia, Ying
Ren, Guofeng
Haudek, Sandra
Leucker, Thorsten
Kraemer, Daniela
Taffet, George
Rollins, Barrett J.
Entman, Mark L.
机构
[1] Baylor Coll Med, Methodist Hosp, Cardiovasc Sci Sect, Houston, TX 77030 USA
[2] Baylor Coll Med, Methodist Hosp, DeBakey Heart Ctr, Houston, TX 77030 USA
[3] Univ Bonn, Dept Cardiac Surg, D-5300 Bonn, Germany
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
关键词
inflammation; ischemia; reperfusion; immunology; pathology; fibrosis; cardiomyopathy;
D O I
10.1161/CIRCULATIONAHA.106.646091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Cardiac interstitial fibrosis plays an important role in the pathogenesis of ischemic cardiomyopathy, contributing to systolic and diastolic dysfunction. We have recently developed a mouse model of fibrotic noninfarctive cardiomyopathy due to brief repetitive myocardial ischemia and reperfusion. In this model, fibrotic changes are preceded by marked and selective induction of the CC chemokine monocyte chemoattractant protein-1 (MCP-1). We hypothesized that MCP-1 may mediate fibrotic remodeling through recruitment of mononuclear cells and direct effects on fibroblasts. Methods and Results - Wild-type (WT) and MCP-1-null mice underwent daily 15-minute coronary occlusions followed by reperfusion. Additional WT animals received intraperitoneal injections of a neutralizing anti-MCP-1 antibody after the end of each ischemic episode. Hearts were examined echocardiographically and processed for histological and RNA studies. WT mice undergoing repetitive brief myocardial ischemia and reperfusion protocols exhibited macrophage infiltration after 3 to 5 days and marked interstitial fibrosis in the ischemic area after 7 days, accompanied by ventricular dysfunction. MCP-1-null mice had markedly diminished interstitial fibrosis, lower macrophage infiltration, and attenuated ventricular dysfunction compared with WT animals. MCP-1 neutralization also inhibited interstitial fibrosis, decreasing left ventricular dysfunction and regional hypocontractility. Cardiac myofibroblasts isolated from WT but not from MCP-1-null animals undergoing repetitive myocardial ischemia and reperfusion demonstrated enhanced proliferative capacity. However, MCP-1 stimulation did not induce cardiac myofibroblast proliferation and did not alter expression of fibrosis-associated genes. Conclusions - Defective MCP-1 signaling inhibits the development of ischemic fibrotic cardiomyopathy in mice. The profibrotic actions of MCP-1 are associated with decreased macrophage recruitment and may not involve direct effects on cardiac fibroblasts.
引用
收藏
页码:584 / 592
页数:9
相关论文
共 50 条
  • [21] Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling
    Ishibashi, M
    Hiasa, K
    Zhao, QW
    Inoue, S
    Ohtani, K
    Kitamoto, S
    Tsuchihashi, M
    Sugaya, T
    Charo, IF
    Kura, S
    Tsuzuki, T
    Ishibashi, T
    Takeshita, A
    Egashira, K
    CIRCULATION RESEARCH, 2004, 94 (09) : 1203 - 1210
  • [22] CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts
    Dewald, O
    Zymek, P
    Winkelmann, K
    Koerting, A
    Ren, GF
    Abou-Khamis, T
    Michael, LH
    Rollins, BJ
    Entman, ML
    Frangogiannis, NG
    CIRCULATION RESEARCH, 2005, 96 (08) : 881 - 889
  • [23] Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy
    Iwasaki, Jun
    Nakamura, Kazufumi
    Matsubara, Hiromi
    Nakamura, Yoichi
    Nishii, Nobuhiro
    Banba, Kimikazu
    Murakami, Masato
    Ohta-Ogo, Keiko
    Kimura, Hideo
    Toh, Norihisa
    Nagase, Satoshi
    Oka, Takefumi
    Morita, Hiroshi
    Kusano, Kengo Fukushima
    Ohe, Tohru
    CARDIOVASCULAR PATHOLOGY, 2009, 18 (06) : 317 - 322
  • [24] Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy
    Banba, N
    Nakamura, T
    Matsumura, M
    Kuroda, H
    Hattori, Y
    Kasai, K
    KIDNEY INTERNATIONAL, 2000, 58 (02) : 684 - 690
  • [25] A small synthetic molecule capable of preferentially inhibiting the production of the CC chemokine monocyte chemotactic protein-1
    Sironi, M
    Guglielmotti, A
    Polentarutti, N
    Fioretti, F
    Milanese, C
    Romano, M
    Vigini, C
    Coletta, I
    Sozzani, S
    Bernasconi, S
    Vecchi, A
    Pinza, M
    Mantovani, A
    EUROPEAN CYTOKINE NETWORK, 1999, 10 (03) : 437 - 441
  • [26] Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis
    Baron, P
    Bussini, S
    Cardin, V
    Corbo, M
    Conti, G
    Galimberti, D
    Scarpini, E
    Bresolin, N
    Wharton, SB
    Shaw, PJ
    Silani, V
    MUSCLE & NERVE, 2005, 32 (04) : 541 - 544
  • [27] Monocyte chemoattractant protein-1 and atherosclerosis: Is there room for an additional biomarker?
    Coll, Blai
    Alonso-Villaverde, Carlos
    Joven, Jorge
    CLINICA CHIMICA ACTA, 2007, 383 (1-2) : 21 - 29
  • [28] Monocyte chemoattractant protein-1: A key mediator in inflammatory processes
    Melgarejo, Esther
    Angel Medina, Miguel
    Sanchez-Jimenez, Francisca
    Luis Urdiales, Jose
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (05): : 998 - 1001
  • [29] Monocyte Chemoattractant Protein-1 in Dogs Affected with Neoplasia or Inflammation
    Ishioka, Katsumi
    Suzuki, Yumi
    Tajima, Kana
    Ohtaki, Sumire
    Miyabe, Masahiro
    Takasaki, Mariko
    Mori, Akihiro
    Momota, Yutaka
    Azakami, Daigo
    Sako, Toshinori
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2013, 75 (02): : 173 - 177
  • [30] Monocyte chemoattractant protein-1 levels in patients with glomerular disease
    Rovin, BH
    Doe, N
    Tan, LC
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (05) : 640 - 646